Lilly Statement Regarding NIH’s ACTIV-3 Clinical Trial

/statement-activ3-clinical-trial-nih-cov

Kassem @kassem CC BY-NC-SA 13/10/2020

Monoclonal Antibody Trial Halted for Safety Concern | Brief19
▻https://brief19.com/2020/10/13/monoclonal-antibody-trial-halted-for-safety-concern
https://brief19.com/images/brief19.jpg

(En association avec le #remdesivir dans l’étude concernée appelée “ACTIV-3”)
This news casts doubt as to the wisdom and safety of the approach used by President Trump’s medical team.
#anticorps_monoclonaux

Kassem @kassem CC BY-NC-SA
- Kassem @kassem CC BY-NC-SA 27/10/2020
  
  Définitivement arrêté pour cause d’inefficacité; concernait des malades hospitalisés uniquement.
  Lilly Statement Regarding NIH’s ACTIV-3 Clinical Trial | Eli Lilly and Company
  ▻https://www.lilly.com/news/stories/statement-activ3-clinical-trial-nih-covid19
  
  Kassem @kassem CC BY-NC-SA
- Kassem @kassem CC BY-NC-SA 23/12/2020
  
  A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19 | NEJM
  ▻https://www.nejm.org/doi/full/10.1056/NEJMoa2033130
  https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/0/nejm.ahead-of-print/nejmoa2033130/20201222/images/img_small/nejmoa2033130_f1.jpeg
  
  Kassem @kassem CC BY-NC-SA
Écrire un commentaire